Fundamentals Hub
ACBM ACRO BIOMEDICAL CO., LTD.
ACBM financial statements, revenue, balance sheet, cash flow, and SEC filings
▼ Company Profile
▼ Key Metrics (TTM)
As of Jun 30, 2026Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | - | - | $0 |
| Gross Profit | - | - | $0 |
| OPERATING EXPENSES | |||
| R&D Expense | - | $0 | $4.79M |
| SG&A Expense | $154.02K | $37.96K | $3.52M |
| Other Operating Expenses (derived) | - | - | $492.00K |
| Operating Income | $-154.02K | $-37.96K | $-8.80M |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Expense | - | - | $3.21K |
| Other Income/Expense | $52.88K | $-4.34K | - |
| Pretax Income | $-101.15K | $-42.30K | $-8.81M |
| Income Tax | $0 | $0 | $0 |
| Net Income | $-101.15K | $-42.30K | $-8.81M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $0.00 | $0.00 | $-0.15 |
| Diluted Shares | 60.04M | 60.04M | 60.04M |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $4.10K | $476 | $376 |
| Accounts Receivable | - | - | $0 |
| Other Current Assets | $10.00K | $0 | $1.25K |
| Current Assets | $14.10K | $5.08K | $1.63K |
| Noncurrent Assets | $0 | $26.90K | $56.83K |
| Total Assets | $14.10K | $31.97K | $58.46K |
| LIABILITIES | |||
| Accounts Payable | $55.55K | $154.46K | $154.44K |
| Other Current Liabilities | - | - | $88.80K |
| Current Liabilities | $401.06K | $326.95K | $288.58K |
| Noncurrent Liabilities | $0 | $0 | $26.90K |
| Total Liabilities | $401.06K | $326.95K | $315.47K |
| EQUITY | |||
| Common Stock | $60.04K | $60.04K | $60.04K |
| Additional Paid-in Capital | $32.31M | $32.30M | $32.30M |
| Retained Earnings | $-32.76M | $-32.66M | $-32.62M |
| Total Equity | $-386.96K | $-294.97K | $-257.01K |
| Total Liabilities & Equity | $14.10K | $31.97K | $58.46K |
| SUPPLEMENTAL | |||
| Shares Outstanding | 60.04M | 60.04M | 60.04M |
| Check: A − (L + E + Temp. Equity) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-196.30K | $-36.69K | $-15.45K |
| Capital Expenditures | - | - | - |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $199.92K | $36.79K | $9.97K |
| Free Cash Flow | - | - | - |
| Beginning Cash (CFS) | $476 | $376 | $5.85K |
| Net Change in Cash | $3.62K | $100 | $-5.48K |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | $4.10K | $476 | $376 |
| Cash per BS | $4.10K | $476 | $376 |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $4.10K | $476 | $376 |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log InQuarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
What is ACRO BIOMEDICAL CO., LTD.'s annual revenue?
ACRO BIOMEDICAL CO., LTD. reported $0 in revenue for trailing twelve months (ending June 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.
Is ACRO BIOMEDICAL CO., LTD. profitable?
No. ACRO BIOMEDICAL CO., LTD. reported $-140.41K in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.